Mirae Asset Global ETFs Holdings
LCTX icon

Mirae Asset Global ETFs Holdings’s Lineage Cell Therapeutics LCTX Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Buy
+84,857
New +$117K ﹤0.01% 2770
2025
Q2 		– Sell
-104,061
Closed -$47K – 3132
2025
Q1 		$47K Buy
104,061
+19,352
+23% +$11.3K ﹤0.01% 2863
2024
Q4 		$42.6K Buy
84,709
+3,648
+5% +$2.68K ﹤0.01% 2930
2024
Q3 		$73.4K Buy
81,061
+14,354
+22% +$13.3K ﹤0.01% 2824
2024
Q2 		$66.5K Buy
+66,707
New +$73.7K ﹤0.01% 2713

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Mirae Asset Global ETFs Holdings's LCTX Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 84,857 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #2770 among its holdings. This is a return to the name: Mirae Asset Global ETFs Holdings previously reported a position in LCTX as recently as Q1 2025.

Mirae Asset Global ETFs Holdings first reported a position in LCTX in Q2 2024 and has held it in 5 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Mirae Asset Global ETFs Holdings held 84,857 shares of Lineage Cell Therapeutics worth $111K as of Q2 2026.
  • Lineage Cell Therapeutics was a new Mirae Asset Global ETFs Holdings position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #2770 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Lineage Cell Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.